financetom
Business
financetom
/
Business
/
Westinghouse Air Brake Technologies Insider Sold Shares Worth $6,740,603, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Westinghouse Air Brake Technologies Insider Sold Shares Worth $6,740,603, According to a Recent SEC Filing
Nov 4, 2024 11:20 AM

03:14 PM EDT, 11/01/2024 (MT Newswires) -- Albert J Neupaver, Director, on October 30, 2024, sold 35,722 shares in Westinghouse Air Brake Technologies ( WAB ) for $6,740,603. Following the Form 4 filing with the SEC, Neupaver has control over a total of 614,447 shares of the company, with 614,447 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/943452/000094345224000163/xslF345X05/wk-form4_1730487940.xml

Price: 187.95, Change: -0.03, Percent Change: -0.02

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Mars set to win unconditional EU nod for $36 billion Kellanova deal, sources say
Mars set to win unconditional EU nod for $36 billion Kellanova deal, sources say
Oct 7, 2025
BRUSSELS, Oct 7 (Reuters) - Candy and snacks giant Mars' $36 billion bid to acquire Pringles maker Kellanova ( K ) is set to clear a major hurdle by winning unconditional European Union antitrust approval, three people with direct knowledge of the matter said. The deal, among the biggest in the sector, would bring under one roof brands ranging from...
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment
Lexeo Says FDA Open to Application Submission for Accelerated Approval of Friedreich Ataxia Cardiomyopathy Treatment
Oct 7, 2025
07:23 AM EDT, 10/07/2025 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Tuesday the US Food and Drug Administration has indicated openness to a biologics license application submission for accelerated approval of its LX2006 candidate for the treatment of Friedreich ataxia cardiomyopathy. The submission will include interim clinical data from ongoing phase I/II studies of LX2006 pooled with new...
Mars set to win unconditional EU nod for $36 billion Kellanova deal, sources say
Mars set to win unconditional EU nod for $36 billion Kellanova deal, sources say
Oct 7, 2025
BRUSSELS (Reuters) -Candy and snacks giant Mars' $36 billion bid to acquire Pringles maker Kellanova ( K ) is set to clear a major hurdle by winning unconditional European Union antitrust approval, three people with direct knowledge of the matter said. The deal, among the biggest in the sector, would bring under one roof brands ranging from M&Ms, Snickers and...
Eli Lilly Reports 4 Years of Sustained Remission in Patients With Ulcerative Colitis
Eli Lilly Reports 4 Years of Sustained Remission in Patients With Ulcerative Colitis
Oct 7, 2025
07:21 AM EDT, 10/07/2025 (MT Newswires) -- Eli Lilly ( LLY ) said Tuesday that data from its phase 3 open-label extension study showed that its drug Omvoh, or mirikizumab-mrkz, achieved sustained clinical, endoscopic and steroid-free remission over four years in patients with moderate to severely active ulcerative colitis. After four years of treatment, the company said that 78% of...
Copyright 2023-2026 - www.financetom.com All Rights Reserved